New Dawn At Novartis As Narasimhan Demands Breakthroughs
Vas Narasimhan says it’s not enough to develop drugs that are first- or best-in-class, they have to be transformational in the benefits they offer patients and society at large. CAR-T therapy Kymriah fits the bill.
You may also be interested in...
Novartis’ Data-Centric R&D Strategy Adds Pact With UK-based Big Data Institute
Novartis and the Big Data Institute have entered a research alliance using artificial intelligence to understand complex diseases and improve drug development.
Novartis UK Moves To London To Seek Its Life Sciences Digital Fortune
Novartis is to move its UK headquarters to London to be at the heart of the new technology and life sciences in the west of the city.
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.